W
Wendy J. Huss
Researcher at Roswell Park Cancer Institute
Publications - 46
Citations - 2069
Wendy J. Huss is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 20, co-authored 34 publications receiving 1913 citations. Previous affiliations of Wendy J. Huss include Baylor College of Medicine & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.
Paula Kaplan-Lefko,Tsuey Ming Chen,Michael Ittmann,Michael Ittmann,Roberto Barrios,Gustavo Ayala,Wendy J. Huss,Lisette A. Maddison,Barbara A. Foster,Norman M. Greenberg +9 more
TL;DR: Windows of opportunity are defined in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer as a paradigm for designing pre‐clinical trials for prostate cancer trials.
Journal ArticleDOI
Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism
Jianqun Liao,Feng Qian,Nana Tchabo,Paulette Mhawech-Fauceglia,Amy Beck,Zikun Qian,Xinhui Wang,Wendy J. Huss,Shashikant Lele,Carl Morrison,Kunle Odunsi +10 more
TL;DR: In insight into the relationship between tumor dissemination and metabolic attributes of human cancer stem cells, spheroid cells were found to be enriched for cells with cancer stem cell-like characteristics and contributed to tumor generation, progression and chemotherapy resistance.
Journal Article
Angiogenesis and prostate cancer: identification of a molecular progression switch.
TL;DR: This resolution of prostate cancer-associated angiogenesis into distinct early and late molecular events establishes the basis for a "progression-switch" model to explain how the targets of antiangiogenic therapy might change as a function of tumor progression.
Journal ArticleDOI
Breast Cancer Resistance Protein–Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem Cells
TL;DR: BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem Cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.
Journal ArticleDOI
Oct4A is expressed by a subpopulation of prostate neuroendocrine cells
TL;DR: Stem cell properties of self‐renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative spliced variant, Oct4B, is unknown.